Roche Ag (OTC: RHHBY)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Roche Ag Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Roche Ag Company Info
News & Analysis
Which of these companies is better able to replace declining COVID-19-related sales?
None
You really can build a high-performing portfolio that advances sustainability initiatives.
The company has posted growth despite lower demand for several key products.
Their liquid biopsies are giving doctors new and better tools to spot, track, and treat cancers.
GenMark appears to be a good fit for Roche's diagnostics business.
While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.
The deal will provide the pharma giant with a unique new platform for tackling autoimmune diseases.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/01/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.